Condition
Elective Percutaneous Coronary Intervention
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (1)
P 4 (1)
Trial Status
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05708053Phase 3UnknownPrimary
Cardio-protective Effect of Metformin in Patients Undergoing PCI
NCT03406832Not ApplicableUnknown
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
NCT00433784Phase 4Completed
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel
Showing all 3 trials